Get started
Author

Martin Eduardo Richardet

Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma
2021 · Toni K. Choueiri, Thomas Powles, et al. · New England Journal of Medicine · 1,870
PDF
Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial
2020 · Robert J. Motzer, Bernard Escudier, et al. · Cancer · 329
PDF
Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025
2017 · Bernard Escudier, Robert J. Motzer, et al. · European Urology · 240
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial
2015 · M. Schuler, J.C.-H. Yang, et al. · Annals of Oncology · 132
PDF
696O_PR Nivolumab + cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: First results from the randomized phase III CheckMate 9ER trial
2020 · T.K. Choueiri, T. Powles, et al. · Annals of Oncology · 117
PDF
Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial
2024 · T. Powles, M. Burotto, et al. · ESMO Open · 112
Nivolumab + cabozantinib (NIVO+CABO) versus sunitinib (SUN) for advanced renal cell carcinoma (aRCC): Outcomes by sarcomatoid histology and updated trial results with extended follow-up of CheckMate 9ER.
2021 · Robert J. Motzer, Toni K. Choueiri, et al. · Journal of Clinical Oncology · 74
Weekly regimen of irinotecan/docetaxel in previously treated non-small cell lung cancer patients and correlation with uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) polymorphism
2003 · Albert Font, José Miguel Sánchez, et al. · Investigational New Drugs · 66
Nivolumab plus cabozantinib vs sunitinib for first-line treatment of advanced renal cell carcinoma (aRCC): 3-year follow-up from the phase 3 CheckMate 9ER trial.
2023 · Mauricio Burotto, Thomas Powles, et al. · Journal of Clinical Oncology · 48
Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trial
2025 · R.J. Motzer, B. Escudier, et al. · Annals of Oncology · 43
PDF
Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden
2024 · Michael Schenker, Mauricio Burotto, et al. · Journal for ImmunoTherapy of Cancer · 43
PDF
Subcutaneous versus intravenous nivolumab for renal cell carcinoma
2024 · L. Albiges, M.T. Bourlon, et al. · Annals of Oncology · 32
Final analysis of the CheckMate 025 trial comparing nivolumab (NIVO) versus everolimus (EVE) with >5 years of follow-up in patients with advanced renal cell carcinoma (aRCC).
2020 · Robert J. Motzer, Scott S. Tykodi, et al. · Journal of Clinical Oncology · 30
Nivolumab plus cabozantinib (N+C) vs sunitinib (S) for previously untreated advanced renal cell carcinoma (aRCC): Results from 55-month follow-up of the CheckMate 9ER trial.
2024 · Maria Teresa Bourlon, Bernard Escudier, et al. · Journal of Clinical Oncology · 29
PDF
VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor–Positive/HER2−/PIK3CA Wild-Type Advanced Breast Cancer
2026 · Sara A. Hurvitz, Rachel M. Layman, et al. · Journal of Clinical Oncology · 26
Abstract CT022: CheckMate 848: A randomized, open-label, phase 2 study of nivolumab in combination with ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden
2022 · Michael Schenker, Mauricio Burotto, et al. · Cancer Research · 26
Nivolumab plus cabozantinib (N+C) vs sunitinib (S) for previously untreated advanced renal cell carcinoma (aRCC): Final follow-up results from the CheckMate 9ER trial.
2025 · Robert J. Motzer, Bernard Escudier, et al. · Journal of Clinical Oncology · 16
Treatment beyond progression with nivolumab (nivo) in patients (pts) with advanced renal cell carcinoma (aRCC) in the phase III CheckMate 025 study.
2016 · Bernard J. Escudier, Robert J. Motzer, et al. · Journal of Clinical Oncology · 16
Phase II non-randomized study of three different sequences of docetaxel and vinorelbine in patients with advanced non-small cell lung cancer
2002 · José Miguel Sánchez, Carme Balañá, et al. · Lung Cancer · 12
A randomized, open-label, phase 3 study of gedatolisib + fulvestrant ± palbociclib vs standard of care in HR+/HER2−/ PIK3CA -mutant (MT) advanced breast cancer (VIKTORIA-1 Study 2).
2026 · Sara A. Hurvitz, Giuseppe Curigliano, et al. · Journal of Clinical Oncology · 9
Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMIS
2024 · Neal D Shore, Christian Gratzke, et al. · The Oncologist · 9
Nivolumab plus docetaxel versus placebo plus docetaxel for androgen receptor pathway inhibitor-pretreated and chemotherapy-naive metastatic castration-resistant prostate cancer (CheckMate 7DX): a double-blind, randomised, phase 3 trial
2025 · Karim Fizazi, Fred Saad, et al. · The Lancet Oncology · 7
Safety of darolutamide (DARO) for nonmetastatic castration-resistant prostate cancer (nmCRPC) from extended follow-up in the phase III ARAMIS trial.
2021 · Matthew Raymond Smith, Karim Fizazi, et al. · Journal of Clinical Oncology · 3
Abstract RF7-04: Gedatolisib, a multi-target PI3K/AKT/mTOR (PAM) inhibitor, plus fulvestrant with or without palbociclib for second-line (2L) treatment of patients with HR+/HER2-/PIK3CA-wild type (WT) advanced breast cancer (ABC): updated results from the randomized, phase 3 VIKTORIA-1 trial
2026 · B. Pistilli, R. Layman, et al. · Clinical Cancer Research · 2
Subcutaneous nivolumab versus intravenous nivolumab in patients with previously treated, advanced, or metastatic clear cell renal cell carcinoma.
2022 · Matias Rodrigo Chacon, Hernan J. Cutuli, et al. · Journal of Clinical Oncology · 2
Works count: 67
Citation count: 3,303
H-index: 16
I10-index: 19
Year
Topic
Type